New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...

Eli Lilly has scored a major victory in its battle for the US diabetes drug market after a trial showed its Trulicity cut risk of cardiovascular events, even in patients who had no prior history ...

Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. With a volume of ...

In 2025, Lilly also expects an unfavorable impact from foreign exchange rates on the top line. Sales of Trulicity are likely to have been hurt by competitive dynamics and lower realized prices in ...